IP Library › Granted Patent US 8,957,046
Granted Patent B2
US 8,957,046 · App. 14/254,737 · Granted Feb 17, 2015

Nucleoside phosphoramidate prodrugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,957,046
App. No.
14/254,737
Granted
Feb 17, 2015
Kind
B2
Abstract

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Claims (2)

1. A method of treating a human infected by hepatitis C virus, comprising administering to the subject an effective amount of an NS3 inhibitor and an effective amount of a compound represented by the following formula:

2. The method of claim 1 , wherein the NS3 inhibitor is a compound represented by the following formula:

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2022
From: GILEAD PHARMASSET LLC
To: GILEAD SCIENCES, INC.
Reel/Frame 058890/0229 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2014
From: DU, JINFA; NAGARATHNAM, DHANAPALAN; SOFIA, MICHAEL JOSEPH; WANG, PEIYUAN
To: PHARMASSET, INC.
Reel/Frame 033404/0944 →
CHANGE OF NAME Recorded Jul 28, 2014
From: PHARMASSET, INC.
To: GILEAD PHARMASSET LLC
Reel/Frame 033429/0375 →